Galderma is launching Sculptra in China.
The poly-L-lactic acid (PLLA-SCA)-based filler was approved by China’s National Medical Products Administration for correcting mid-facial volume loss and/or contour deficiencies last year.
The approval was based on results from a study in China, which showed Sculptra’s ability to achieve high and maintained response rates in the correction of midface volume/contour deficit through to two years.
“I am very excited by Sculptra’s introduction to the Chinese market, as it allows me to provide my patients with a distinctive product renowned for its exceptional safety and effectiveness,” says Dr. Haiyan Cui, Director of the Department of Plastic and Cosmetic Surgery of Tongji Hospital of Tongji University in China. “Sculptra restores a youthful appearance and enhances skin quality, all while maintaining a natural look and feel, and I am looking forward to offering it to my patients in China.”
